Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

BioNTech raises €290m for mRNA cancer vaccine platform

BioNTech raises €290m for mRNA cancer vaccine platform

BioNTech also has a phase 1 trial on the go for a Sanofi-partnered cancer immunotherapy - SAR441000 – on its own and with Sanofi’s PD-1 drug Libtayo (cemiplimab). ... Following behind are three in-house mRNA vaccines based on the German biotech’s

Latest news

  • Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

    Beyond the ongoing EMPOWER-CSCC-1 trial, Libtayo is also being investigated in adjuvant and neoadjuvant trials in CSCC and in potential registrational trials in non-small cell lung cancer, basal ... Sanofi and Regeneron aren’t holding back on the scale

  • AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

    The phase 3 CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed,” said Baselga. ... including new NSCLC settings and head and neck cancer –

  • Liver cancer failure dents Opdivo potential by $1bn, says analyst Liver cancer failure dents Opdivo potential by $1bn, says analyst

    Merck’s drug has caught and overtaken Opdivo largely because it has come to dominate the first-line non-small cell lung cancer (NSCLC) market – after Opdivo failed a late-stage ... patients. William Blair points to a number of upcoming trials in NSCLC

  • Merck says it has plenty in the pipe beyond Keytruda Merck says it has plenty in the pipe beyond Keytruda

    There’s certainly no sign of Keytruda slowing anytime soon, with new indications still rolling in, most recently for first-line head and neck cancer and second-line small cell lung ... cancer (SCLC), and with momentum only just starting to gather in

  • Keytruda begins pursuit of rivals in small cell lung cancer Keytruda begins pursuit of rivals in small cell lung cancer

    Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Keytruda has also recently been filed as a first-line treatment for head and neck cancer, for use as a

More from news
Approximately 6 fully matching, plus 99 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.

  • Immunisation politicised Immunisation politicised

    Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test. ... For example, the remarkable silence around the fact that some strains of

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,

  • Havas Lynx reflect horror of skin cancer in innovative light reactive poster campaign

    The campaign was devised for HSS Hire, the national tool and equipment hire company, supported by Cancer Research UK. ... Sixty construction workers die each year from skin cancers, with 80% of those located on the head and neck.  A shocking 55% of

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics